Targeted literature review of the humanistic and economic burden of adult growth hormone deficiency

References

• Kargi AY, Merriam GR. Diagnosis and treatment of growth hormone deficiency in adults. Nat Rev Endocrinol 2013;9:335-45
   PubMed Web of Science ®Google Scholar
• Colao A, di Somma C, Cuocolo A, et al. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metabol 2001;86:1874-81
   PubMed Web of Science ®Google Scholar
• Colao A, di Somma C, Pivonello R, et al. The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J Clin Endocrinol Metabol 2002;87:1088-93
   PubMed Web of Science ®Google Scholar
• Reed ML, Merriam GR, Kargi AY. Adult growth hormone deficiency – benefits, side effects, and risks of growth hormone replacement. Front Endocrinol (Lausanne) 2013;4:1-14
   PubMedGoogle Scholar
• Thomas JD, Monson JP. Adult GH deficiency throughout lifetime. Eur J Endocrinol 2009;161(Suppl 1):97-106
   Web of Science ®Google Scholar
• Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid and protein metabolism in human subjects. Endocr Rev 2009;30:152-77
   PubMed Web of Science ®Google Scholar
• Monson JP, Brooke AM, Akker S. Adult growth hormone deficiency. In: De Groot LJ, Chrousos G, Dungan K, et al., eds. Endotext. South Dartmouth, MA: MDText.com Inc; 2015.
   Google Scholar
• Hernberg-Ståhl E, Luger A, Abs R, et al. Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. J Clin Endocrinol Metab 2001;86:5277-81
   Google Scholar
• Holmer H, Svensson J, Rylander L, et al. Psychosocial health and levels of employment in 851 hypopituitary Swedish patients on long-term GH therapy. Psychoneuroendocrinology 2013;38:842-52
   PubMed Web of Science ®Google Scholar
• Koltowska-Häggström M. Quality of life and growth hormone deficiency in adult patients in clinical evaluation and health economic assessment. Pediatr Endocrinol Diabetes Metabol 2009;15:203-9
   PubMedGoogle Scholar
• Koltowska-Häggström M, Mattsson AF, Shalet SM. Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. Eur J Endocrinol/European Federation of Endocrine Societies 2009;161(Suppl 1):S51-S64
   PubMed Web of Science ®Google Scholar
• Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol 2011;96:1587-609
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol 2016;101:3888-921
   PubMed Web of Science ®Google Scholar
• Bex M, Bouillon R. Growth hormone and bone health. Hormone Res 2003;60(Suppl 3):80-6
   Google Scholar
• Verhelst J, Abs R. Cardiovascular risk factors in hypopituitary GH-deficient adults. Eur J Endocrinol/European Federation of Endocrine Societies 2009;161(Suppl 1):S41-S9
   PubMed Web of Science ®Google Scholar
• Gupta V. Adult growth hormone deficiency. Ind J Endocrinol Metabol 2011;15(Suppl 3):S197-202
   Google Scholar
• Koltowska-Häggström M, Jonsson B, Isacson D, Bingefors K. Using EQ-5D to derive general population-based utilities for the quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA). Value Health 2007;10:73-81
   PubMed Web of Science ®Google Scholar
• Moock J, Albrecht C, Friedrich N, et al. Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the Study of Health in Pomerania. Eur J Endocrinol/European Federation of Endocrine Societies 2009;160:17-24
   PubMed Web of Science ®Google Scholar
• Koltowska-Häggström M, Mattsson AF, Monson JP, et al. Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life? Eur J Endocrinol/European Federation of Endocrine Societies 2006;155:109-19
   PubMed Web of Science ®Google Scholar
• Appelman-Dijkstra NM, Claessen KM, Roelfsema F, et al. Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. Eur J Endocrinol/European Federation of Endocrine Societies 2013;169:R1-14
   PubMed Web of Science ®Google Scholar
• Ahmid M, Perry CG, Ahmed SF, Shaikh MG. Growth hormone deficiency during young adulthood and the benefits of growth hormone replacement. Endocrine Connections 2016;5:R1-11
   PubMed Web of Science ®Google Scholar
• Elbornsson M, Gotherstrom G, Bosaeus I, et al. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol 2013;4(64):1-14
   PubMed Web of Science ®Google Scholar
• .Gotherstrom G, Bengtsson BA, Bosaeus I, et al. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab 2007;92:1442-5
   Google Scholar
• Gotherstrom G, Elbornsson M, Stibrant-Sunnerhagen K, et al. Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults. J Clin Endocrinol Metab 2009;94:809-16
   PubMed Web of Science ®Google Scholar
• Barake M, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab 2014;99:852-60
   PubMed Web of Science ®Google Scholar
• Kokshoorn NE, Biermasz NR, Roelfsema F, et al. GH replacement therapy in elderly GH-deficient patients: a systematic review. Eur J Endocrinol 2011(Suppl);164(5):657-665
   Google Scholar
• Rubeck KZ, Bertelsen S, Vestergaard P, Jorgensen JO. Impact of GH substitution on exercise capacity and muscle strength in GH-deficient adults: a meta-analysis of blinded, placebo-controlled trials. Clin Endocrinol (Oxf) 2009;71:860-6
   PubMed Web of Science ®Google Scholar
• Widdowson WM, Gibney J. The effect of growth hormone (GH) replacement on muscle strength in patients with GH-deficiency: a meta-analysis. Clin Endocrinol (Oxf) 2010;72:787-92
   PubMed Web of Science ®Google Scholar
• Xue P, Wang Y, Yang J, Li Y. Effects of growth hormone replacement therapy on bone mineral density in growth hormone deficient adults: a meta-analysis. Int J Endocrinol 2013;2013:216107
   Web of Science ®Google Scholar
• Saller B, Mattsson AF, Kann PH, et al. Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults – comparison between Sweden, The Netherlands and Germany. Eur J Endocrinol/European Federation of Endocrine Societies 2006;154:843-50
   Google Scholar
• Jørgensen AP, Fougner KJ, Ueland T, et al. Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. Growth Hormone IGF Res 2011;21(2):69-75
   PubMed Web of Science ®Google Scholar
• Oświęcimska JM, Roczniak W, Romanowicz D, et al. Quality of life in transition phase in adolescents and young adults with severe and partial growth hormone deficiency. Neuro Endocrinol Lett 2014;35:676-83
   PubMed Web of Science ®Google Scholar
• Svensson J, Mattsson A, Rosén T, et al. Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. Growth Horm IGF Res 2004;4:207-215
   Google Scholar
• Mo D, Blum WF, Rosilio M, et al. Ten-year change in quality of life in adults on growth hormone replacement for growth hormone deficiency: an analysis of the hypopituitary control and complications study. J Clin Endocrinol Metab 2014;99:4581-8
   PubMed Web of Science ®Google Scholar
• Brod M, Hojbjerre L, Adalsteinsson JE, Rasmussen MH. Assessing the impact of growth hormone deficiency and treatment in adults: development of a new disease-specific measure. J Clin Endocrinol Metab 2014;99:1204-12
   PubMed Web of Science ®Google Scholar
• Brod M, Wilkinson L, Højbjerre L, et al. The treatment-related impact measure for adults with growth hormone deficiency (TRIM-AGHD): calculating and interpreting the minimally important difference. In: ISPOR 21st Annual International Meeting, Washington DC, USA, 2016
   Google Scholar
• Ishii H, Shimatsu A, Okimura Y, et al. Development and validation of a new questionnaire assessing quality of life in adults with hypopituitarism: Adult Hypopituitarism Questionnaire (AHQ). PloS One 2012;7:e44304
   PubMed Web of Science ®Google Scholar
• Hofman M, Ryan JL, Figueroa-Moseley CD, et al. Cancer-related fatigue: the scale of the problem. Oncologist 2007;12(Suppl 1):4-10
   PubMed Web of Science ®Google Scholar
• Smith MM, Arnett PA. Factors related to employment status changes in individuals with multiple sclerosis. Mult Scler (Houndmills, Basingstoke, England) 2005;11:602-9
   PubMed Web of Science ®Google Scholar
• Baker K, Pope J, Fortin P, et al. Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factors. Lupus 2009;18:1281-8
   Google Scholar